Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.30341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Noninvasive Ultra Low Intensity Light Photodynamic Treatment of Glioblastoma with Drug Augmentation: LoGlo PDT Regimen.
Brain Sci
November 2024
Neurosurgery Department-Neuro-Oncology, Instituto de Neurologia de Curitiba, Rua Jeremias Maciel Perretto, 300-Campo Comprido, Curitiba 81210-310, Brazil.
This paper presents the basis for LoGlo PDT, a new treatment for glioblastoma. Glioblastoma is currently treated with maximal safe resection, temozolomide, and ionizing irradiation. Mortality in 2024 remains over 80% within several years from diagnosis.
View Article and Find Full Text PDFHigh-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.
Nat Med
November 2024
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we systematically screened repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform.
View Article and Find Full Text PDFClinical Correlation of Transcription Factor SOX3 in Cancer: Unveiling Its Role in Tumorigenesis.
Genes (Basel)
June 2024
Division of Mathematics and Sciences, Walsh University, North Canton, OH 44720, USA.
Members of the SOX (SRY-related HMG box) family of transcription factors are crucial for embryonic development and cell fate determination. This review investigates the role of SOX3 in cancer, as aberrations in SOX3 expression have been implicated in several cancers, including osteosarcoma, breast, esophageal, endometrial, ovarian, gastric, hepatocellular carcinomas, glioblastoma, and leukemia. These dysregulations modulate key cancer outcomes such as apoptosis, epithelial-mesenchymal transition (EMT), invasion, migration, cell cycle, and proliferation, contributing to cancer development.
View Article and Find Full Text PDFUnderstanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review.
Cancers (Basel)
May 2024
Department of Neurosurgery, University Hospital Marburg, 35033 Marburg, Germany.
Background: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in the development, progression, and therapeutic potential of glioblastomas.
Methodology: The study, following PRISMA guidelines, systematically examined hypoxia and HIFs in glioblastoma using MEDLINE (PubMed), Web of Science, and Scopus. A total of 104 relevant studies underwent data extraction.
Integrative spatial analysis reveals a multi-layered organization of glioblastoma.
Cell
May 2024
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Electronic address:
Article Synopsis
- Gliomas consist of malignant cells that exhibit various cellular states, which are organized in distinct ways within the tumor.
- Research reveals three key modes of organization: localized environments with predominant cellular states, specific pairings of these states residing close to one another, and a global architecture consisting of five layers driven by hypoxia.
- The study emphasizes that hypoxia influences the spatial arrangement of these cellular states, while regions far from hypoxic areas show less organization, offering a novel framework for understanding glioma structure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!